5-Amino-1MQ: The Research-Grade NNMT Inhibitor for Fat Loss

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

5-Amino-1MQ has become one of the most talked-about metabolic research compounds of the last few years, and for an unusual reason: in obese mice, knocking down the same enzyme it targets cut fat mass without changing how much the animals ate. That single observation, published in Nature, sparked a wave of interest in whether the pathway could be drugged with a small molecule. This guide explains what 5-Amino-1MQ actually is, the enzyme it blocks, what the early science does and does not show, how researchers have dosed it, its reported side effects, and how it stacks up against NAD+ precursors like NMN. You will leave with an honest, evidence-anchored picture rather than hype. Importantly, this is a research-grade compound studied only in animals and cells so far, not a licensed medicine, and nothing here is medical advice.

Table of Contents

• What Is 5-Amino-1MQ?
• How Does 5-Amino-1MQ Work?
• Key Benefits & Uses of 5-Amino-1MQ
• 5-Amino-1MQ Side Effects, Safety & Dosage
• What Does the Research Say?
• 5-Amino-1MQ vs Alternatives (NMN, NAD+, MOTS-c)
• How to Use 5-Amino-1MQ — Practical Guidance
• Frequently Asked Questions
• The Bottom Line

Reviewed by the Clinical Pharmacology Lead, MedsBase Medical Review Team · Last updated: 24 May 2026

What Is 5-Amino-1MQ? (Definition & Background)

It is worth stating plainly: 5-Amino-1MQ is not a peptide. Many “fat loss” research compounds sold alongside it, such as Tesamorelin or MOTS-c, are peptide chains of amino acids that usually require reconstitution and injection. 5-Amino-1MQ is a single small molecule based on a quinolinium ring, which is why studies have been able to dose it orally.

Chemically, it is a derivative of methylquinolinium designed to occupy the active site of NNMT. NNMT is an enzyme that becomes overexpressed in adipose (fat) tissue and the liver in obesity, which made it an attractive target for researchers asking whether you could reverse some metabolic dysfunction by switching it off.

At MedsBase, 5-Amino-1MQ is stocked as part of our research-grade line for laboratory and reference use. It sits within the broader category of compounds explored for metabolic and longevity research, which is why it is often grouped with our peptide and research-compound catalogue even though, strictly, it belongs to a different chemical class.

How Does 5-Amino-1MQ Work? (NNMT Inhibition & NAD+)

The mechanism is the most interesting part of the 5-Amino-1MQ story. As an NNMT inhibitor, it targets a single metabolic bottleneck. Understanding that bottleneck explains why researchers think it could matter for fat metabolism.

NNMT consumes two important molecules to do its job. It takes nicotinamide (a form of vitamin B3, closely tied to NAD+) and a methyl donor called S-adenosylmethionine (SAM), and combines them. In obesity, NNMT is overexpressed, so it burns through more nicotinamide and SAM than usual.

When you inhibit NNMT with a compound like 5-Amino-1MQ, the theory is that nicotinamide and SAM are spared. More nicotinamide can be recycled back into NAD+, the central coenzyme of cellular energy. Higher intracellular NAD+ and SAM in white fat cells are associated, in animal models, with increased energy expenditure rather than fat storage. In short, the cell is nudged toward burning rather than hoarding.

Infographic text (for indexability): The proposed pathway runs in four steps. Step 1: NNMT is overexpressed in obese fat and liver tissue. Step 2: it consumes nicotinamide and SAM. Step 3: 5-Amino-1MQ binds NNMT and blocks this reaction. Step 4: spared nicotinamide is recycled into NAD+, intracellular NAD+ and SAM rise, and white fat cells shift toward higher energy expenditure in animal models. The net research observation is reduced fat mass without reduced food intake.

This NAD+ angle is why 5-Amino-1MQ is frequently discussed as an indirect NAD+ booster. Rather than supplying NAD+ building blocks the way NMN or NR do, it tries to stop NAD+ being wasted in the first place. For more on why NAD+ itself attracts so much research interest, see our guide to NAD+ benefits and the honest science.

Key Benefits & Uses of 5-Amino-1MQ

It is important to frame these as reported research outcomes in animal models, not proven human benefits. With that caveat, here are the areas researchers focus on.

Fat loss and reduced fat mass

The headline interest in 5-Amino-1MQ benefits is body fat. In diet-induced-obese mouse studies, small-molecule NNMT inhibition has been associated with reduced fat mass and improved metabolic markers without forced calorie restriction. As a fat loss compound, its appeal is that it appears to act on fat-cell metabolism directly rather than by suppressing appetite.

NAD+ support and the NAD+ booster angle

By sparing nicotinamide, 5-Amino-1MQ may help preserve the NAD+ pool inside cells. NAD+ declines with age and is essential for mitochondrial energy production, which is why an NAD+ booster mechanism draws so much attention in longevity research circles.

Metabolic activity

Beyond fat, NNMT activity is linked to insulin sensitivity and SAM-dependent methylation reactions. Early studies indicate that modulating this enzyme can shift several metabolic parameters at once, which is why it is described as a metabolic research compound rather than a narrow “fat burner”.

Energy and mitochondrial function

Because NAD+ feeds mitochondrial energy production, research interest also extends to cellular energy and exercise-related metabolism. This remains hypothetical in humans and rests on the same NAD+ logic described above.

Infographic text (for indexability): Four research focus areas for 5-Amino-1MQ. One, fat mass reduction in diet-induced-obese mice. Two, NAD+ support via sparing of nicotinamide. Three, broad metabolic effects including methylation and insulin-related pathways. Four, mitochondrial energy. Every item is preclinical; none is a proven human benefit.

5-Amino-1MQ Side Effects, Safety & Dosage

Honesty matters here. Because there are no human clinical trials, the human safety profile of 5-Amino-1MQ is essentially unknown. What follows is drawn from animal research and anecdotal reports, and should be read as a list of possible effects, not an established profile.

Research dosing context (not a recommendation)

The 5-Amino-1MQ dosage ranges discussed in informal research settings typically sit in the region of 50–150 mg per day taken orally, often once daily. We share this only to describe what appears in the literature and community reports, not as guidance to follow. Because no regulator has established a safe human dose, any figure should be treated as unvalidated.

The single most important safety point is that NNMT touches methylation and NAD+ metabolism, which are fundamental to many tissues. Inhibiting a core metabolic enzyme could have effects that animal studies have not yet revealed. Anyone considering 5-Amino-1MQ should do so only under qualified clinical supervision and after honest discussion of these unknowns.

What Does the Research Say?

The evidence base for 5-Amino-1MQ is built almost entirely on the NNMT-targeting hypothesis. Below is a summary of the anchor research, with qualifying language throughout.

The pattern is consistent: the foundational science is strong at the level of the target, but the compound itself has not been tested in humans. Early studies indicate promise in animal models; that is genuinely different from a proven therapy. We will not overstate it.

Infographic text (for indexability): Evidence ladder for 5-Amino-1MQ. Rung one, target validation in mice via genetic knockdown — strong. Rung two, small-molecule inhibition reducing fat mass in obese mice — moderate, preclinical. Rung three, human clinical trials — none exist. The compound sits at preclinical evidence only.

5-Amino-1MQ vs Alternatives (NMN, NAD+, MOTS-c)

People researching 5-Amino-1MQ usually compare it with other compounds tied to NAD+ and metabolism. The key distinction is mechanism: 5-Amino-1MQ tries to spare NAD+, while NMN and NAD+ try to supply it.

If your research interest is fat metabolism specifically, 5-Amino-1MQ is unusual because it is oral and acts on fat-cell enzymes. If your interest is replenishing NAD+ broadly, NMN and NAD+ approaches take a different, supply-side route. For a wider comparison, see our roundup of the best peptides for fat loss, which covers several of these alternatives side by side.

How to Use 5-Amino-1MQ — Practical Guidance

Because 5-Amino-1MQ is studied as an oral small molecule, it does not behave like an injectable peptide. In animal studies it was given by mouth, and most research-grade material is supplied as a capsule or powder rather than a vial for reconstitution.

This matters practically: unlike many peptides, 5-Amino-1MQ typically does not require mixing with bacteriostatic water. If you are working with peptides that do need preparation, our guide on how to reconstitute peptides walks through that process, but it generally does not apply to 5-Amino-1MQ in capsule form.

For anyone handling it in a research context, the sensible principles are: confirm purity and identity with a certificate of analysis, store it cool and dry away from light and moisture, keep meticulous records, and never treat informal community dosing as validated. Because there is no established human dose, conservatism is the only defensible position.

Browse our research-grade 5-Amino-1MQ to review specifications, purity documentation and current availability. As always, this is reference research material, not a treatment we are recommending you take.

Frequently Asked Questions

What does 5-Amino-1MQ do?

5-Amino-1MQ inhibits the enzyme NNMT (nicotinamide N-methyltransferase). In animal research, blocking this enzyme appears to spare nicotinamide and SAM, raise intracellular NAD+, and increase energy expenditure in fat cells. The observed result in mice is reduced fat mass without reduced food intake. In humans, none of this has been confirmed, so its real-world effects remain unproven.

Is 5-Amino-1MQ safe?

The honest answer is that its human safety is unknown because there have been no clinical trials. Animal studies and anecdotal reports suggest mostly mild issues such as nausea or headache, but inhibiting a core metabolic enzyme could have effects not yet identified. It is a research-grade compound, not a licensed medicine, and should only be considered under qualified clinical supervision after weighing these unknowns.

5-Amino-1MQ vs NMN — what is the difference?

They approach NAD+ from opposite directions. 5-Amino-1MQ tries to spare NAD+ by stopping the enzyme that wastes its precursor, while NMN supplies NAD+ building blocks for the body to convert. NMN has some early human data; 5-Amino-1MQ does not. Both are oral, but they are different chemical classes targeting different points in NAD+ metabolism.

Does 5-Amino-1MQ cause weight loss?

In diet-induced-obese mice, NNMT inhibition has been associated with reduced fat mass, which is why it is studied as a fat loss compound. However, this has never been demonstrated in a human clinical trial. Any claim that 5-Amino-1MQ causes weight loss in people goes beyond the evidence. It should be viewed as a promising research hypothesis, not a proven slimming agent.

How long does 5-Amino-1MQ take to work?

There is no validated human timeline because no human trials exist. In animal studies, metabolic changes developed over weeks of dosing rather than days. Any community timelines you see are anecdotal and unverified. Without controlled clinical data, it is not possible to give a reliable answer, and you should be sceptical of confident claims about onset.

Is 5-Amino-1MQ a peptide?

No. This is a common misconception. 5-Amino-1MQ is a small synthetic molecule built on a quinolinium ring, not a chain of amino acids. It is frequently sold alongside peptides because it shares the metabolic and longevity research space, but chemically it belongs to a different class and is orally active rather than injectable.

How is 5-Amino-1MQ dosed in research?

Informal research and community reports describe oral 5-Amino-1MQ dosage in roughly the 50–150 mg per day range, often once daily. This is descriptive only and not a recommendation. Because no regulatory body has established a safe human dose, any number should be treated as unvalidated, and decisions should involve a qualified clinician.

What makes 5-Amino-1MQ different as a metabolic research compound?

Most NAD+-related approaches supply precursors. 5-Amino-1MQ instead blocks the enzyme that depletes the precursor, acting as an indirect NAD+ booster. It is also orally bioavailable in studies and works on fat-cell metabolism directly. That combination is why it stands out among metabolic research compounds, even though the human evidence is still absent.

The Bottom Line

5-Amino-1MQ is one of the more scientifically grounded entries in the metabolic research space, and it earns that status honestly: the enzyme it targets, NNMT, has solid validation as a metabolic switch in animal models. The compound’s oral activity and its indirect NAD+-sparing mechanism make it genuinely distinct from NMN, direct NAD+, and injectable peptides like MOTS-c.

But the gap between “interesting target” and “proven therapy” is wide. There are no human clinical trials, the human safety profile is uncharacterised, and any dose you encounter is unvalidated. Treat 5-Amino-1MQ as exactly what it is — a research-grade compound for laboratory and reference use, not a medicine. If you are exploring it for that purpose, you can review specifications and purity documentation on our research-grade 5-Amino-1MQ page, and discuss any practical questions with a qualified professional first.

Reviewed by the MedsBase Medical Review Team. See our editorial policy.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.